寿玮龄;崔巍;

• 1:中国医学科学院 北京协和医学院 北京协和医院检验科

摘要(Abstract)：

<正>1865年Trousseau首次报道了1例疑诊胃癌的患者发生游走性血栓静脉炎,半年后该患者确诊为肿瘤;1878年Billroth发现恶性肿瘤患者的血栓中存在肿瘤细胞,推测血栓与肿瘤转移可能存在相关性。随后的临床观察、实验室检查及动物模型研究证明,恶性肿瘤发生发展过程中存在不同程度的凝血纤溶机制异常,而凝血纤溶系统的改变与肿瘤病理分期、转移及预后密切相关。有效的抗凝治疗可以延长恶性肿瘤患者的生存时间,改善其生活质量,但临床

关键词(KeyWords)： 恶性肿瘤;出凝血异常;机制

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 寿玮龄;崔巍;

Email:

DOI:

参考文献(References)：

• [1]Blom JW,Doggen CJ,Osanto S,et al.Malignancies,pro-thrombotic mutations,and the risk of venous thrombosis[J].JAMA,2005,293:715-722.
• [2]Noble S,Pasi J.Epidemiology and pathophysiology of can-cer-associated thrombosis[J].Br J Cancer,2010,102(Suppl1):S2-S9.
• [3]Krger K,Weiland D,Ose C,et al.Risk factors for venous thromboembolics in cancer patients[J].Ann Oncol,2006,17:297-303.
• [4]Prandoni P,Lensing AW,Piccioli A,et al.Recurrent ve-nous thromboembolism and bleeding complications during an-ticoagulant treatment in patients with cancer and venous thrombosis[J].Blood,2002,100:3484-3488.
• [5]Srensen HT,Svrke C,Farkas DK,et al.Superficial and deep venous thrombosis,pulmonary embolism and subse-quent risk of cancer[J].Eur J Cancer,2012,48:586-593.
• [6]Falanga A,Marchetti M.Venous thromboembolism in hema-tologic malignancies[J].J Clin Oncol,2009,27:4848-4857.
• [7]Geerts WH,Pineo GF,Heit JA,et al.Prevention of venous thromboembolism:the Seventh ACCP Conference on an-tithrombotic and thrombolytic therapy[J].Chest,2004,126(3Suppl):338S-400S.
• [8]Franchini M,Montagnana M,Targher G.Pathogenesis,clin-ical and laboratory aspects of thrombosis in cancer[J].J Thromb Thrombolysis,2007,24:29-38.
• [9]Ay C,Dunkler D,Pirker R,et al.High D-dimer levels are associated with poor prognosis in cancer patients[J].Haematologica,2012,97:1158-1164.
• [10]Kasthuri RS,Taubman MB,Mackman N.Role of tissue fac-tor in caner[J].J Clin Oncol,2009,27:4834-4838.
• [11]Boccaccio C,Comoglio PM.Genetic link between cancer and thrombosis[J].J Clin Oncol,2009,27:4827-4833.
• [12]Falanga A,Barbui T,Rickles FR.Hypercoagulability and tissue factor gene upregulation in hematologic malignancies[J].Semin Thromb Hemost,2008,34:204-210.
• [13]Lee AY.Cancer and thromboembolic disease:pathogenic me-chanisms[J].Cancer Treat Rev,2002,28:137-140.
• [14]Nash GF,Turner LF,Scully MF,et al.Platelets and cancer[J].Lancet Oncol,2002,3:425-430.
• [15]Aharon A,Brenner B.Microparticles,thrombosis and can-cer[J].Best Pract Res Clin Haematol,2009,22:61-69.
• [16]Davila M,Amirkhosravi A,Coll E,et al.Tissue factor-bear-ing microparticles derived from tumor cells:impact on coagu-lation activation[J].J Thromb Haemost,2008,6:1517-1524.
• [17]De Cicco M.The prothrombotic states in cancer:pathogenic mechanisms[J].Crit Rev Oncol Hematol,2004,50:187-196.
• [18]Shivakumar SP,Anderson DR,Couban S.Catheter-associ-ated thrombosis in patients with malignancies[J].J Clin Oncol,2009,27:4858-4864.
• [19]Baronzio G,Freitas I,Kwaan HC,et al.Tumor microenviron-ment and hemorheological abnormalities[J].Semin Thromb Hemost,2003,29:489-498.
• [20]Barbera L,Thomas G.Erythropoiesis stimulating agents,th-rombosis and cancer[J].Radiother Oncol,2010,95:269-276.
• [21]Miesbach W,Scharrer I,Asherson R.Thrombotic manifesta-tions of the antiphospholipid syndrome in patients with malig-nancies[J].Clin Rheumatol,2006,25:840-844.
• [22]Zacharski LR.Hypercoagulability preceding cancer[J].J Thromb Haemost,2005,3:585-588.
• [23]Menell JS,Cesarman GM,Jacovina AT,et al.Annexin II and bleeding in acute promyelocytic leukemia[J].N Engl J Med,1999,340:994-1004.
• [24]Liu Y,Jiang P,Capkova K,et al.Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy[J].Cancer Res,2011,71:6492-6502.
• [25]Otrock ZK,Hatoum HA,Awada AH,et al.Hypoxia-indu-cible factor in cancer angiogensis:structure,regulation and clinical perspectives[J].Crit Rev Oncol Hematol,2009,70:93-102.
• [26]Khorana AA,Ahrendt SA,Ryan CK,et al.Tissue factor expression,angiogenesis and thrombosis in pancreatic cancer[J].Clin Cancer Res,2007,13:2870-2875.
• [27]Versteeg HH,Schaffner F,Kerver M,et al.Inhibition of tissue factor signaling suppresses tumor growth[J].Blood,2008,111:190-199.
• [28]Zigler M,Kamiya T,Brantley EC,et al.PAR-1and throm-bin:the ties that bind the microenvironment to melanoma metastasis[J].Cancer Res,2011,71:6561-6566.
• [29]McMahon B,Kwaan HC.The plasminogen activator system and cancer[J].Pathophysiol Haemost Thromb,2007,8:184-194.
• [30]彭黎明,邓承祺.现代血栓与止血的实验室检测及其应用[M].北京:人民卫生出版社,2004.
• [31]Streiff MB.Diagnosis and initial treatment of venous throm-boembolism in patients with cancer[J].J Clin Oncol,2009,27:4889-4894.
• [32]Lyman GH,Khorana AA,Falanga A,et al.American Soci-ety of Clinical Oncology guideline:recommendations for ve-nous thromboembolism prophylaxis and treatment in patients with cancer[J].J Clin Oncol,2007,25:5490-5505.
• [33]Petersen LJ.Anticoagulation therapy for prevention and treat-ment of venous thromboembolic events in cancer patients:a review of current guidelines[J].Cancer Treat Rev,2009,35:754-764.